Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo
October 2, 2026 · 11:15 AM · NEW YORK
Pfizer Inc. (NYSE: PFE) today presented results from two Phase 3 trials evaluating the efficacy and safety of LITFULO® (ritlecitinib) as a once-daily oral treatment across a wide range of disease extent. In the two studies, TRANQUILLO 2 and TRANQUILLO, LITFULO 100 mg and 50 mg, respectively, significantly improved facial and total body repigmentation compared to placebo. These improvements were supported by patient-reported outcomes indicating reduced disease severity and meaningful change in facial and total body vitiligo, as well as greater disease stabilization compared to placebo. These results from the largest Phase 3 program to date evaluating an oral systemic therapy for nonsegmental vitiligo (NSV) were presented today in a late-breaking oral presentation at the 35th European Academy of Dermatology and Venereology (EADV) Annual Congress in Vienna, Austria.
- PublishedOctober 2, 2026 · 11:15 AM
- LocationNEW YORK
- IndustryHealth
- LanguageEN
Published by Business Wire. Read the original announcement for the full release.
Read the full announcement →
